Literature DB >> 31199668

The alarmin S100A9 hampers osteoclast differentiation from human circulating precursors by reducing the expression of RANK.

Irene Di Ceglie1, Arjen B Blom1, Robab Davar2, Colin Logie2, Joost H A Martens2, Ehsan Habibi2, Lisa-Marie Böttcher1, Johannes Roth3, Thomas Vogl3, Carl S Goodyear4, Peter M van der Kraan1, Peter L van Lent1, Martijn H van den Bosch1.   

Abstract

The alarmin S100A8/A9 is implicated in sterile inflammation-induced bone resorption and has been shown to increase the bone-resorptive capacity of mature osteoclasts. Here, we investigated the effects of S100A9 on osteoclast differentiation from human CD14+ circulating precursors. Hereto, human CD14+ monocytes were isolated and differentiated toward osteoclasts with M-CSF and receptor activator of NF-κB (RANK) ligand (RANKL) in the presence or absence of S100A9. Tartrate-resistant acid phosphatase staining showed that exposure to S100A9 during monocyte-to-osteoclast differentiation strongly decreased the numbers of multinucleated osteoclasts. This was underlined by a decreased resorption of a hydroxyapatite-like coating. The thus differentiated cells showed a high mRNA and protein production of proinflammatory factors after 16 h of exposure. In contrast, at d 4, the cells showed a decreased production of the osteoclast-promoting protein TNF-α. Interestingly, S100A9 exposure during the first 16 h of culture only was sufficient to reduce osteoclastogenesis. Using fluorescently labeled RANKL, we showed that, within this time frame, S100A9 inhibited the M-CSF-mediated induction of RANK. Chromatin immunoprecipitation showed that this was associated with changes in various histone marks at the epigenetic level. This S100A9-induced reduction in RANK was in part recovered by blocking TNF-α but not IL-1. Together, our data show that S100A9 impedes monocyte-to-osteoclast differentiation, probably via a reduction in RANK expression.-Di Ceglie, I., Blom, A. B., Davar, R., Logie, C., Martens, J. H. A., Habibi, E., Böttcher, L.-M., Roth, J., Vogl, T., Goodyear, C. S., van der Kraan, P. M., van Lent, P. L., van den Bosch, M. H. The alarmin S100A9 hampers osteoclast differentiation from human circulating precursors by reducing the expression of RANK.

Entities:  

Keywords:  S100A8/A9; bone; epigenetic regulation

Mesh:

Substances:

Year:  2019        PMID: 31199668     DOI: 10.1096/fj.201802691RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  4 in total

1.  S100A8/A9 is not essential for the development of inflammation and joint pathology in interleukin-1 receptor antagonist knockout mice.

Authors:  Irene Di Ceglie; Peter L E M van Lent; Edwin J W Geven; Marije I Koenders; Arjen B Blom; Thomas Vogl; Johannes Roth; Martijn H J van den Bosch
Journal:  Arthritis Res Ther       Date:  2021-08-19       Impact factor: 5.156

Review 2.  Macrophage-Derived Extracellular Vesicles as Carriers of Alarmins and Their Potential Involvement in Bone Homeostasis.

Authors:  Bartijn C H Pieters; Alfredo Cappariello; Martijn H J van den Bosch; Peter L E M van Lent; Anna Teti; Fons A J van de Loo
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

3.  Plumbagin, a Biomolecule with (Anti)Osteoclastic Properties.

Authors:  Sevinj Sultanli; Soni Ghumnani; Richa Ashma; Katharina F Kubatzky
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

4.  S100 Calcium Binding Protein A9 Represses Angiogenic Activity and Aggravates Osteonecrosis of the Femoral Head.

Authors:  Re-Wen Wu; Wei-Shiung Lian; Chung-Wen Kuo; Yu-Shan Chen; Jih-Yang Ko; Feng-Sheng Wang
Journal:  Int J Mol Sci       Date:  2019-11-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.